- Conditions: Hodgkin Disease; Hodgkin Lymphoma
Interventions: Drug: Filgrastim; Drug: Plerixafor; Drug: Yttrium-Daclizumab (CHX-A Daclizumab); Drug: Carmustine; Drug: Etoposide; Drug: Cytarabine; Drug: Melphalan; Drug: Ca(2+)-DTPA
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011 - Condition: Relapsing Remitting Multiple Sclerosis
Intervention: Biological: Daclizumab High Yield Process prefilled syringe
Sponsors: Biogen Idec; Biogen Idec; Abbott Biotherapeutics Corp.
Recruiting - verified April 2012 - Conditions: Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting
Intervention: Biological: DAC-HYP
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified January 2012 - Conditions: Chemotherapy; Tumor; Ovarian Cancer
Intervention: Biological: OCDC
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified May 2012 - Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: Interferon β 1a; Drug: DAC HYP
Sponsors: Biogen Idec; Biogen Idec; Abbott Biotherapeutics Corp.
Recruiting - verified March 2012 - Condition: Adult T-Cell Leukemia (ATL)
Interventions: Drug: LMB-2; Drug: Fludarabine; Drug: Cyclophosphamide; Drug: LMB-2, anti-Tac(Fv)-PE38
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Type 1 Diabetes Mellitus
Intervention: Procedure: Islet transplant
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified December 2011 - Conditions: Positive Hairy Cell Leukemia; CD25-Expressing Hairy Cell Leukemia
Intervention: Biological: LMB-2
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified July 2011 - Conditions: Cutaneous T Cell Lymphoma; Hodgkin's Disease; Neoplasm; Non Hodgkin's Lymphoma; Peripheral T Cell Lymphoma
Interventions: Drug: Y-90 Humanized Anti-Tac; Drug: Calcium-DTPA
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified July 2011
 |
Daclizumab Clinical Trials |
